Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

162.78 -1.22 (-0.74%)

Streaming Delayed Price Updated: 1:31 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Volume	195,868
Open	164.05
Bid (Size)	161.72 (100)
Ask (Size)	163.85 (100)
Prev. Close	164.00
Today's Range	160.00 - 166.00
52wk Range	49.00 - 170.25
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

InvestorNewsBreaks – Belite Bio, Inc (NASDAQ: BLTE) Prices $350M Underwritten Public Offering of ADSs

December 05, 2025

Via Investor Brand Network

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

December 01, 2025

From Belite Bio, Inc

Via GlobeNewswire

Performance

YTD	+2.2%	+2.2%
1 Month	+9.2%	+9.2%
3 Month	+107.4%	+107.4%
6 Month	+162.4%	+162.4%
1 Year	+191.0%	+191.0%

More News

Why Belite Bio Stock Soared on Monday ↗

December 01, 2025

Via The Motley Fool

Earnings Scheduled For November 10, 2025 ↗

November 10, 2025

Via Benzinga

Earnings Outlook For Belite Bio ↗

November 07, 2025

Via Benzinga

Belite Bio's Earnings Outlook ↗

August 08, 2025

Via Benzinga

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares

December 01, 2025

From Belite Bio, Inc

Via GlobeNewswire

Top movers in Monday's pre-market session ↗

December 01, 2025

Via Chartmill

New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease

December 01, 2025

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

November 10, 2025

From Belite Bio, Inc

Via GlobeNewswire

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

November 05, 2025

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results

November 03, 2025

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

November 02, 2025

From Belite Bio, Inc

Via GlobeNewswire

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 31, 2025

From Virtual Investor Conferences

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

October 30, 2025

From Virtual Investor Conferences

Via GlobeNewswire

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

October 29, 2025

From Virtual Investor Conferences; Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

October 29, 2025

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Participate in the 2025 Maxim Growth Summit

October 16, 2025

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

October 15, 2025

From Belite Bio, Inc

Via GlobeNewswire

3 Lesser-Known Healthcare Names With Major Upside in Store ↗

October 02, 2025

Via MarketBeat

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

September 12, 2025

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

September 08, 2025

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio to Participate in Three Upcoming Investor Conferences

August 27, 2025

From Belite Bio, Inc

Via GlobeNewswire

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

August 11, 2025

From Belite Bio, Inc

Via GlobeNewswire

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Frequently Asked Questions

Is Belite Bio, Inc - American Depositary Shares publicly traded?

Yes, Belite Bio, Inc - American Depositary Shares is publicly traded.

What exchange does Belite Bio, Inc - American Depositary Shares trade on?

Belite Bio, Inc - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Belite Bio, Inc - American Depositary Shares?

The ticker symbol for Belite Bio, Inc - American Depositary Shares is BLTE on the Nasdaq Stock Market

What is the current price of Belite Bio, Inc - American Depositary Shares?

The current price of Belite Bio, Inc - American Depositary Shares is 162.78

When was Belite Bio, Inc - American Depositary Shares last traded?

The last trade of Belite Bio, Inc - American Depositary Shares was at 01/09/26 01:31 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.